Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial

Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation

(2009) Dirk Kuck et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies

(2009) T. E. Fandy et al.   BLOOD

Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes

(2009) M. T. Voso et al.   CLINICAL CANCER RESEARCH

5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome - a systematic review and meta-analysis

(2009) R. Gurion et al.   HAEMATOLOGICA

Blockade of MEK signaling potentiates 5-Aza-2′-deoxycytidine-induced apoptosis and upregulation of p21waf1 in acute myelogenous leukemia cells

(2009) Chie Nishioka et al.   INTERNATIONAL JOURNAL OF CANCER

DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic Syndromes

(2009) Lanlan Shen et al.   JOURNAL OF CLINICAL ONCOLOGY

In vitro basis for treatment with hypomethylating agents and histone deacetylase inhibitors: can epigenetic changes be used to monitor treatment?

(2009) Steven D. Gore   LEUKEMIA RESEARCH

Association between CpG Island Methylation of the WWOX Gene and Its Expression in Breast Cancers

(2009) X. Wang et al.   TUMOR BIOLOGY

Update on the therapy for myelodysplastic syndrome

(2008) Margaret T. Kasner et al.   AMERICAN JOURNAL OF HEMATOLOGY

Current status of epigenetic treatment in myelodysplastic syndromes

(2008) Andrea Kuendgen et al.   ANNALS OF HEMATOLOGY

Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression

(2008) Yinhong Song et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Valproic acid as epigenetic cancer drug: Preclinical, clinical and transcriptional effects on solid tumors

(2008) Alfonso Duenas-Gonzalez et al.   CANCER TREATMENT REVIEWS

A Phase I Biological Study of MG98, an Oligodeoxynucleotide Antisense to DNA Methyltransferase 1, in Patients with High-Risk Myelodysplasia and Acute Myeloid Leukemia

(2008) R. B. Klisovic et al.   CLINICAL CANCER RESEARCH

Demethylating agents in myeloid malignancies

(2008) Guillermo Garcia-Manero   CURRENT OPINION IN ONCOLOGY

Epigenetic and HIF-1 regulation of stanniocalcin-2 expression in human cancer cells

(2008) Alice Y.S. Law et al.   EXPERIMENTAL CELL RESEARCH

p21WAF1/CIP1 induction by 5-azacytosine nucleosides requires DNA damage

(2008) A Jiemjit et al.   ONCOGENE